Abstract
In the well-developed countries, breast cancer-related mortality rates show decreasing tendency. Relapse occurs only in about one-fourth of all patients. According to randomized studies, no survival benefit is provided in these cases by practising intensive follow-up including instrumental studies to actively search for distant metastases. The most important role of patient surveillance is to detect early-stage, potentially curable isolated local/regional relapses or second primary breast cancers. More and more attention is given to the early detection and treatment of the side-effects of the therapy on the other hand. Even a “minimalist” follow-up practice maintains the relationship with the patient that is important for getting reassurance for compliance with adjuvant endocrine therapies, assistance in case of symptoms of metastasis, or if medical or social decisions are to be made. Sometimes psychological problems occur, which necesitate special support. In routine practice, regular visits including patient history, physical examination, and breast imaging studies on a 6–12 monthly basis for up to 5 years and yearly thereafter with the maintenance of a supportive relationship with the patient are recommended. Chest, abdominal or bone imaging studies, laboratory or tumor marker tests are justified only in suspicion of relapse.
Similar content being viewed by others
References
Khatcheressian JL, Hurley P, Bantug E, et al. American Society of Clinical Oncology. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:961–5.
Aebi S, Davidson T, Gruber G, Cardoso F. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22 (suppl 6):vi12–24.
NCCN. 2013. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. version 1.2014.
Partridge AH, Winer EP, Burstein HJ. Follow-up care of breast cancer survivors. Semin Oncol. 2003;30:817–25.
Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA. 1994;271:1593–7.
Palli D, Russo A, Saieva C, et al. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up. JAMA. 1999;281:1586.
GIVIO. Impact of follow-up testing on survival and health-related quality oflife in breast cancer patients. A multicenter randomized controlled trial. JAMA. 1994;271:1587–92.
Grunfeld E, Mant D, Yudkin P, et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ. 1996;313:665–9.
Kokko R, Hakama M, Holli K. Follow-up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Res Treat. 2005;93:255–60.
Rojas MP, Telaro E, Russo A, Moschetti I, Coe L, Fossati R, et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2005:CD001768.
Winchester DP, Sener SF, Khandekar JD, et al. Symptomatology as an indicator of recurrent or metastatic breast cancer. Cancer. 1979;43:956–60.
Schapira DV, Urban N. A minimalist policy for breast cancer surveillance. JAMA. 1991;265:380–2.
Lee JE, Park SS, Han W, et al. The clinical use of staging bone scan in patients with breast carcinoma: reevaluation by the 2003 American Joint Committee on Cancer staging system. Cancer. 2005;104:499–503.
Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–312.
Mille D, Roy T, Carrère MO, et al. Economic impact of harmonizing medical practices: compliance with clinical practice guidelines in the follow-up of breast cancer in a French Comprehensive Cancer Center. J Clin Oncol. 2000;18:1718–24.
Gulliford T, Opomu M, Wilson E, Hanham I, Epstein R. Popularity of less frequent follow up for breast cancer in randomised study: initial findings from the hotline study. BMJ. 1997;314:174–7.
Loprinzi CL, Hayes D, Smith T. Doc, shouldn’t we be getting some tests? J Clin Oncol. 2000;18:2345–8.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–16.
Kahán Z, Hideghéty K, Varga Z. Breast cancer, a heterogeneous disease entity. The very early stages. Springer, Dordrecht; 2011. Chap. 10, the risks of radiotherapy, and how to avoid them. pp. 241–68.
Liljegren G, Lindgren A, Bergh J, et al. Risk factors for local recurrence after conservative treatment in stage I breast cancer. Definition of a subgroup not requiring radiotherapy. Ann Oncol. 1997;8:235–41.
Holmberg L, Wong YN, Tabár L, et al. Mammography casting-type calcification and risk of local recurrence in DCIS: analyses from a randomised study. Br J Cancer. 2013;108:812–9.
Dorr W, Bertmann S, Herrmann T. Radiation induced lung reactions in breast cancer therapy. Modulating factors and consequential effects. Strahlenther Onkol. 2005;181:567–73.
Johansen J, Overgaard J, Rose C, et al. Cosmetic outcome and breast morbidity in breast-conserving treatment. Acta Oncol. 2002;41:369–80.
Darby SC, Cutter DJ, Boerma M, et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010;76:656–65.
Darby S, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300 000 women in US SEER cancer registries. Lancet Oncol. 2005;6:557–65.
Cuzick J, Stewart H, Rutqvist L, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol. 1994;12:447–53.
Kahán Z. Breast cancer, a heterogeneous disease entity. The very early stages. Springer, Dordrecht; 2011. Chap. 12, systemic therapy: selection of patients. Endocrine therapy. pp. 283–304.
Pagani O, Partridge A, Korde L, et al. Breast International Group; North American Breast Cancer Group Endocrine Working Group. Pregnancy after breast cancer: if you wish, ma’am. Breast Cancer Res Treat. 2011;129:309–17.
Balmaña J, Díez O, Rubio IT, Cardoso F, ESMO Guidelines Working Group. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22 (Suppl 6):vi31–4. doi:10.1093/annonc/mdr373.
Kwast AB, Drossaert CH, Siesling S; follow-up working group. Breast cancer follow-up: from the perspective of health professionals and patients. Eur J Cancer Care (Engl). 2013;22:754–64.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kahán, Z. Breast cancer surveillance: nothing has changed in the past decades (?). memo 7, 22–26 (2014). https://doi.org/10.1007/s12254-014-0136-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-014-0136-x